Teacher Retirement System of Texas Invests $122,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Teacher Retirement System of Texas acquired a new position in shares of ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY – Free Report ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,591 shares of the company’s stock, valued at approximately $122,000.

A number of other large investors also recently modified their holdings of the company. Compass Capital Corp MA ADV purchased a new stake in ARS Pharmaceuticals in the 4th quarter valued at about $106,000. Quarry LP purchased a new position in shares of ARS Pharmaceuticals during the 3rd quarter valued at about $174,000.



Stifel Financial Corp purchased a new position in ARS Pharmaceuticals in the 3rd quarter worth $199,000. Intech Investment Management LLC purchased a new position in ARS Pharmaceuticals in the 3rd quarter worth approximately $239,000. Finally, SBI Securities Co.

Ltd. bought a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth about $175,000. 68.

16% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades Several analysts have commented on the stock. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.

00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th.

They set an “outperform” rating and a $40.00 target price for the company. Raymond James lifted their price target on shares of ARS Pharmaceuticals from $26.

00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd.

Finally, Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price for the company.

Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals In other news, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.

00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,589,359.26.

The trade was a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website .

Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.

00. Following the sale, the insider now directly owns 7,696 shares of the company’s stock, valued at $107,744. This trade represents a 56.

51 % decrease in their position. The disclosure for this sale can be found here . In the last quarter, insiders have sold 159,600 shares of company stock valued at $1,866,516.

Company insiders own 40.10% of the company’s stock. ARS Pharmaceuticals Stock Up 4.

2 % Shares of SPRY opened at $13.05 on Thursday. ARS Pharmaceuticals, Inc.

has a 52-week low of $7.55 and a 52-week high of $18.51.

The business has a fifty day moving average of $12.12 and a 200 day moving average of $13.09.

The company has a market cap of $1.28 billion, a PE ratio of -25.59 and a beta of 1.

03. ARS Pharmaceuticals ( NASDAQ:SPRY – Get Free Report ) last posted its quarterly earnings results on Thursday, March 20th. The company reported $0.

52 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.56.

The company had revenue of $86.58 million during the quarter, compared to analysts’ expectations of $15.46 million.

As a group, research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

About ARS Pharmaceuticals ( Free Report ) ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Featured Stories Five stocks we like better than ARS Pharmaceuticals Market Cap Calculator: How to Calculate Market Cap Homebuilders in Freefall: Bargain Opportunity or Falling Knife? What is a Low P/E Ratio and What Does it Tell Investors? The 3 Most Talked About Investments on WallStreetBets Right Now Best Stocks Under $5.00 Analyst Targets Signal More Growth in CrowdStrike Stock Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc.

( NASDAQ:SPRY – Free Report ). Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

.